These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11745488)

  • 1. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy.
    Chen BM; Cheng TL; Tzou SC; Roffler SR
    Int J Cancer; 2001 Dec; 94(6):850-8. PubMed ID: 11745488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats.
    Chen BM; Chan LY; Wang SM; Wu MF; Chern JW; Roffler SR
    Int J Cancer; 1997 Nov; 73(3):392-402. PubMed ID: 9359487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.
    Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR
    Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
    Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
    Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.
    Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR
    Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.
    Cheng TL; Chen BM; Chern JW; Wu MF; Roffler SR
    Bioconjug Chem; 2000; 11(2):258-66. PubMed ID: 10725103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
    Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of an antineoplastic glucuronide prodrug.
    Cheng TL; Chou WC; Chen BM; Chern JW; Roffler SR
    Biochem Pharmacol; 1999 Jul; 58(2):325-8. PubMed ID: 10423174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity.
    Vingerhoeds MH; Haisma HJ; Belliot SO; Smit RH; Crommelin DJ; Storm G
    Pharm Res; 1996 Apr; 13(4):604-10. PubMed ID: 8710754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
    Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
    J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate.
    Roffler SR; Wang SM; Chern JW; Yeh MY; Tung E
    Biochem Pharmacol; 1991 Oct; 42(10):2062-5. PubMed ID: 1741786
    [No Abstract]   [Full Text] [Related]  

  • 15. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
    Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
    Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
    Haisma HJ; Van Muijen M; Scheffer G; Scheper RJ; Pinedo HM; Boven E
    Hybridoma; 1995 Aug; 14(4):377-82. PubMed ID: 8522350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.
    Cheng TL; Wu PY; Wu MF; Chern JW; Roffler SR
    Bioconjug Chem; 1999; 10(3):520-8. PubMed ID: 10346886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hapten-directed targeting to single-chain antibody receptors.
    Cheng TL; Liao KW; Tzou SC; Cheng CM; Chen BM; Roffler SR
    Cancer Gene Ther; 2004 May; 11(5):380-8. PubMed ID: 15044963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.